| Active tDCS with Sternberg task for neuralgia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Capivasertib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexmedetomidine hydrochloride for dysautonomia, familial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Elraglusib for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ex-cipn for peripheral nervous system diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Imifoplatin for peripheral nervous system diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Leia Sensory Prosthesis for peripheral nervous system diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Methylcobalamin for peripheral nervous system diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Neridronic acid for reflex sympathetic dystrophy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nicotinamide riboside for peripheral nervous system diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| NTLA-2001 for polyneuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Psilocybin for neuralgia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| ROC-101 for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tersolisib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VCA-894A for charcot-marie-tooth disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VER-01 for neuralgia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|